Navigation Links
Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
Date:4/23/2009

o a contemporaneous control of PEGINTRON, full-dose REBETOL and boceprevir for 48 weeks. The primary endpoint of the study was SVR after 24 weeks of follow up. In the study, the 28-week and 48-week boceprevir no lead-in arms had SVR rates of 54 percent (n=58/107) and 67 percent (n=69/103), respectively.

The HCV SPRINT-1 study was conducted at sites across the United States, Canada and Europe. Overall, 77 percent of the 595 patients in the study were enrolled in the United States. African-Americans represented 16 percent of the patients enrolled and 7 percent of the patients in the study were cirrhotic.

Rationale for Lead-In Regimen

The use of the P/R lead-in prior to the addition of boceprevir was shown in the HCV SPRINT-1 study to reduce the incidence of viral breakthrough regardless of treatment duration. The rationale for the lead-in treatment regimen is based on the fact that both PEGINTRON and REBETOL reach steady-state concentrations by week 4, therefore patients have the protease inhibitor added at a time when the backbone drug levels have been optimized and viral load (HCV RNA) has been reduced. In addition, the patient's immune system will have been activated and primed by PEGINTRON at the time that boceprevir is added to the regimen. This approach may minimize the period of time when there is a "functional monotherapy" with a direct antiviral agent, potentially reducing the likelihood for the development of resistance.

About Ongoing Boceprevir Phase III Registration Studies

Patient enrollment has been completed in two ongoing randomized, double-blind, placebo-controlled registration studies evaluating boceprevir in combination with PEGINTRON and REBETOL compared to standard of care with PEGINTRON and REBETOL alone. More than 1,500 patients were enrolled in these studies at U.S. and international sites.

The HCV SPRINT-2 study evaluates the effi
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
2. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
3. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
4. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
6. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
7. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
8. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
9. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
10. The Anatomy of Clinical Trials: Greys Season Finale Leaves Public in the Dark About the Myths and Realities
11. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  ResMed ... has signed a definitive agreement to acquire ... non-invasive ventilation and sleep-disordered breathing medical devices ... innovation and market reputation in China, combined with ResMed,s global leadership in sleep ... in China suffering ...
(Date:7/30/2015)... edition of #MedicareMonday on Medicare,s 50 th anniversary. As Medicare celebrates 50 years, ... the success of the prescription drug benefit, commonly referred to as Part D. ... videos here: http://onphr.ma/1INp9qQ ... ... More ...
(Date:7/30/2015)... July 30, 2015  Amgen (NASDAQ: AMGN ) today ... managing director of Warburg Pincus LLC, to the Amgen Board ... Fred Hassan and the deep, global experience he ... Robert A. Bradway , chairman and chief executive officer ... will serve Amgen well." Mr. Hassan has been ...
Breaking Medicine Technology:ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3
... HealthSouth Corporation (NYSE: HLS ) announced today ... dividend of $16.25 per share on its 6.5% Series A ... holders of record on Oct. 1, 2010. ... rehabilitative healthcare services. Operating in 26 states across the country ...
... Pharmacy announced today they have earned a position of 554 on ... companies in America. "We,re proud to be recognized by ... in the nation, but if you dig a little deeper into ... Phil Hagerman, President and CEO of Diplomat. The details Hagerman refers ...
Cached Medicine Technology:Diplomat Specialty Pharmacy Honored by Inc. Magazine as One of the Nation's Fastest-Growing Companies 2
(Date:8/1/2015)... (PRWEB) , ... August 01, 2015 , ... The condition ... among both men and women often causing pain and discomfort. Those who spend a ... circulatory problem, and Northeast Houston Vein Center is doing what it can to create ...
(Date:8/1/2015)... ... August 01, 2015 , ... Professional Orthopedic ... company has acquired Premier Physical Therapy & Wellness (“Premier”) — with 13 locations ... clinics. , “Our acquisition of Premier Physical Therapy & Wellness solidifies Professional as ...
(Date:8/1/2015)... ... August 01, 2015 , ... “ reTXT ” was featured on ... and coolest applications on the market for iOS, Android, and Windows. Joe Toohey, the ... allows users to clarify, edit and delete any message including ones already sent. , ...
(Date:7/31/2015)... New York (PRWEB) , ... July 31, 2015 , ... ... strut their stuff, Super-Sod debuted their new type of sod called Leisure Time(TM) ... trademark application in process. , To commemorate introduction of this new type of sod, ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Precision Aesthetics ... eight years. It was also the first provider of Exilis non-surgical fat reduction ... sought after procedures it has attracted a large International clientele. Many patients travel ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2
... , , , ... NXTM ), a leading manufacturer of innovative dialysis products, today ... his third annual "Grandpa,s Road Trip" with the NxStage(R) System One(TM). ... provides Mr. Wells the opportunity to fit hemodialysis therapy into his ...
... , SILVER SPRING, Md., Sept. 18 The U.S. ... O Plus assay, as a screening tool designed to detect the presence ... that run on the fully automated Abbott Prism System. , , ... There are two types of HIV. HIV type 1 consists ...
... LOUDOUN COUNTY, Va., Sept. 18 On Sunday, ... wellness partner GlaxoSmithKline, and Men,s Health Network (MHN), will recognize ... awareness ribbons and disease awareness information cards to fans prior ... FedExField. Led by MHN staff, volunteers from GlaxoSmithKline, Sigma Phi ...
... abuse among those who could drink before 21 , FRIDAY, ... a place and time when they could legally buy alcohol ... alcoholics or have a drug problem, even well into adulthood, ... Dr. Karen Norberg, a research instructor in psychiatry at Washington ...
... , , , ... pioneer and leader in the development of Optical Coherence Tomography ... will showcase its advanced FD-OCT(TM) technology, the C7-XR(TM) imaging system, ... CA starting Monday, September 21 through Friday, September 25, 2009. ...
... less cost, study suggests , FRIDAY, Sept. 18 (HealthDay News) ... into signs of heart disease by using cardiac CT scans ... CT scans use X-rays to create cross-sectional images of the ... arteries, but it,s hard to tell if they,re actually preventing ...
Cached Medicine News:Health News:NxStage Patient Takes Dialysis Machine on Third Annual Patient Good-Will Tour 2Health News:NxStage Patient Takes Dialysis Machine on Third Annual Patient Good-Will Tour 3Health News:Men's Health Network, The Washington Redskins and GlaxoSmithKline Team Up for September's Prostate Cancer Awareness Month 2Health News:Lower Drinking Age Linked to Later-Life Problems 2Health News:Lower Drinking Age Linked to Later-Life Problems 3Health News:LightLab(R) Imaging Showcases Advanced OCT System Technology at TCT 2009 2Health News:LightLab(R) Imaging Showcases Advanced OCT System Technology at TCT 2009 3Health News:Researchers Perfect the View of Heart Disease 2
Bayonet fine, smooth - 1/box....
Blunt, with attached cable for Valleylab and other brands generators....
Bipolar hand activated forceps....
Blunt, 20 cm long....
Medicine Products: